TruthArchive.ai - Tweets Saved By @pr0truth
@pr0truth - Ms. Jackie
@KanekoaTheGreat Part 2 Recorded at the Nipah Virus international conference in Singapore on December 9 and 10, 2019. Note: I am NOT saying that #COVID19 came from a lab but, why say there is zero evidence when there is evidence that should be re-examined? #Fauci https://t.co/Ct7VQ5y2Mc
Video Transcript AI Summary
In this video, the speakers discuss the importance of gaining knowledge about emerging diseases and using it to develop vaccines and therapeutics. They emphasize the need to identify the origins of pandemics and allocate resources accordingly. The speakers also mention the challenge of monitoring and evaluating conservation success. They highlight the use of near-term indicators such as training people in high-risk areas and educating communities. However, the ultimate indicators of success are the prevention of infections and policy changes that reduce risk. The speakers provide examples of their achievements, such as listing a disease as notifiable and influencing government decisions.
Full Transcript
Speaker 0: Pandemic SARS. Yeah. Sure. But let's try and insert some of these other related and get a better vaccine.
Speaker 1: And I guess also knowledge of what's there. If you see something emerging, it'd give a head start on making a vaccine or a therapeutic.
Speaker 0: That's true. And better knowledge of where they are as well. So you can put your money into these clinics that matter. And that's one of the big things that we've been trying to push. There's a lot of, The word predict or the word, you know, the, anticipating, forecasting pandemics, it doesn't mean you can stop them.
That's the problem. So what we're trying to do is say, on a global scale, if we can show where they most like to come from, the species they most like to originate in, The people most likely to get affected. A global actor like WHO or a national government can Better allocate resources to the highest risk. It's pretty simple.
Speaker 1: So you're doing a lot of activities. Those are just a few of all the ones you can find. How do you know if you're getting results? I know you publish things, right? Yeah.
Are there any other metrics you use?
Speaker 0: Yeah. Well, You're very good at asking the right questions there, because we do know our strategic plan right now. And our board has said to us, You need to monitor and evaluate better. And it's true. It's notoriously hard to monitor conservation success.
And I think this is a similar problem. You've got near term indicators, like number of people you've trained in villages. We have designed these books called Living safer with bats, living safer with wildlife, translate them into 20 odd different languages. And we educate Folks in villages on these high risk interfaces, how to avoid spillover basically. So Near term indicator, how many people have you taught in community outreach?
Speaker 1: Yeah. Yeah.
Speaker 0: But the real indicators are, have you prevented infections? Or have you had a policy change in a government that reduces risk? And we've done that. I mean, it takes a few years, but we have You know, we've got the amphibian disease, chytridomycosis, listed as a notifiable disease with OIE. We've got, you know, the the Sabah government, is blocking building into some road building into
@pr0truth - Ms. Jackie
@KanekoaTheGreat #WHO Inspector Peter Daszak interview from 2019 talking about doing lab tests with bat virusus in China. He runs a non-profit and is also apart of the WHO Inspectors saying there is NO Evidence of #COVID19 originating from a Lab in #China, https://t.co/YSeKZTPEaY
Video Transcript AI Summary
The speaker discusses the global wildlife trade and its connection to the emergence of new diseases. They focus on SARS and how it originated from a wildlife market. Through surveillance of bats in Southern China, they have discovered over 100 new SARS-related coronaviruses that pose a threat to humans. Some of these coronaviruses can infect human cells and cause SARS-like disease. The speaker emphasizes the need for continued surveillance and understanding of these spillover events, as any one of them could potentially lead to a pandemic. They also mention the challenges in developing vaccines and antivirals for these diverse coronaviruses.
Full Transcript
Speaker 0: Another one is global wildlife trade. What are you doing there?
Speaker 1: Well, we're trying to look at patterns of wildlife trade that include a risk of new diseases emerging. So we're doing a couple of things. So one is around SARS. We focused on SARS, coronavirus emerged from a wildlife market and was the 1st pandemic of this century. So it's a big event.
So we started to trace back from the wildlife market which species carried the virus that came into those markets. We found that it was bats, it's not, civics was the original idea. Right. So then we started looking where did they come from. And we went out to Southern China and did surveillance of bats across Southern China, and we've now found, after 6 or 7 years of doing this, over 100 new SARS related coronaviruses, very close to SARS.
Some of them get into human cells in the lab. Some of them can cause SARS disease in humanized mouse models, and are untreatable with therapeutic monoclonals, and you can't vaccinate against them with the vaccine. So these are a clear and present danger. We've even found people with antibodies in union to SARS related Coronaviruses, so there's like human exposure. We're now doing surveillance.
We're just beginning another 5 years of work to look at cohorts in Southern China to say, well, how frequent does this spillover happen? And is it associated with disease? Because I expect, just like in Indonesia and Bangladesh, there are dozens and dozens of small spillovers going on, on the plant any one time, which we just never see.
Speaker 0: Sure. They never amplify. There are few cases, and they're just absorbed in the illness, the overall illness of the population, right?
Speaker 1: They could say, so who cares? And that's one argument. But our strategy as any one of those could become pandemic. There's a lot of stochasticity in what happens then.
Speaker 0: So if we look at
Speaker 1: all of them, understand patterns, try and reduce the number of spillover events we've got.
Speaker 0: But you're saying these are diverse coronaviruses, and You can't vaccinate against them. There are no antivirals. What what do we what do we do?
Speaker 1: Well, so I I think that coronavirus is a pretty good
@pr0truth - Ms. Jackie
@KanekoaTheGreat Peter Daszak admitting to creating Covid-19 back in a 2017 interview. https://t.co/UDPYuHCM9I
Video Transcript AI Summary
Researchers have discovered various coronaviruses in bats, including ones similar to SARS. They focused on the spike protein, which attaches to cells, and conducted experiments in China. By inserting spike proteins from these viruses into pseudoparticles, they tested their ability to bind to human cells. This process allowed them to understand the potential pathogenicity of the virus in humans.
Full Transcript
Speaker 0: We found other coronaviruses in bats, a whole host of them. Some of them looked very similar to SARS. So we sequence the spike protein, the protein that attaches to cells. Then we well, I didn't do this work, but my colleagues in China did the work. You create the pseudoparticles, you look you insert the spike proteins from those viruses, see if they bind to human cells.
And each step of this, you move closer and closer to this virus, could really become pathogenic in people.